En el caso de Nvax igual que con Moderna, el anuncio de Pfizer de que vendera sus vacunas covid en EEUU el año que viene entre 110 y 130 dolares por vacuna, ayuda a la subida..... Nvax esta vendiendo aprox sobre los 20 dolares la dosis, eso le daria un margen grande para subir precio de vacuna y ser competitiva frente a Pfizer...
Primer cierre SEMANAL superando la MM5 tras 10 semanas consecutivas cerrando por debajo. Target a superar los 21,97 ... de hacerlo se calza el gap diario si confirma el mvto de este semana podriamos tener continuacion la proxima y despues ya lo que nos tenga deparado el ER?
Dejo escenario bullish para el corto plazo.
Recordad que está semana publican las FAANG ... Marcarán el ritmo ...
Te diría que los 21.97$ se ven seguro, y que luego dependerá de los earnings y tal.
No obstante al final te digo que verá los 21.97$ pero que antes si va subiendo es que están distribuyendo para los mismos. Si es al revés, pues eso, la están colando para luego en unos earnings potables -no pueden ser nada más que eso por mucho que se saquen un conejo de la chistera- meter un subidón y luego soltar todo el papel, para que siga su camino otra vez.
Que pasará? Nuestro amigo Stan y cuatro de los suyos lo saben, y me gusta imaginar que se descojonan mientras leen esto. Que será parecido a eso, seguro, además.
El resto de los mortales ya si eso a cogérnosla con papel de fumar, y tal.
#28281
Re: Novavax (NVAX): Un Nuevo Comienzo
Pedroperezw
Flipante, jugando con fuego. Deberían estar prohibído estos jueguecitos. Como se les escape a los humanos NVAX se va a 300 de nuevo.
¿Qué hace que el refuerzo COVID-19 de Novavax sea diferente? La vacuna adyuvada “ha seguido reconociendo las variantes que se presentan”, dice el director ejecutivo de Novavax, Germán Áñez, MD.
El booster de Novavax , NVX-CoV2373, fue autorizado previamente en otras geografías, incluso en la Unión Europea . En los EE. UU., será la tercera dosis de refuerzo de COVID-19, junto con Pfizer-BioNTech y Moderna, disponible después de una serie de vacunas primarias.
En la conferencia IDWeek , nos sentamos con el director ejecutivo de Desarrollo Clínico de Novavax, Germán Áñez, MD, para obtener más información sobre esta nueva vacuna de refuerzo sin ARNm.
Un mes después de recibir la vacuna de refuerzo Novavax, dijo Añéz, los participantes del ensayo tenían títulos de anticuerpos neutralizantes y títulos de IgG de unión que eran aproximadamente 3 veces más altos que después de la vacunación primaria. Esto cumplió con los criterios de no inferioridad.
Añéz dijo que estos resultados se esperaban en gran medida, pero un resultado sorprendente fue lo bien que se desempeñó el refuerzo contra las subvariantes de Omicron. “Probamos muestras contra 3 sabores diferentes de la variante de Omicron, BA.1, BA.2 y BA.5”, dijo, y enfatizó que encontraron títulos altos a pesar de que la vacuna de refuerzo no contiene una secuencia de Omicron.
“Esos títulos fueron tan altos como los títulos observados después de la vacunación primaria contra Wuhan, y eso se correlaciona con una eficacia de más del 90 %”. Añéz dijo que estos resultados se mantuvieron consistentes en variables como el tiempo después de la vacunación y la edad de los participantes.
La tecnología adyuvante de NVX-CoV2373 “está permitiendo que la vacuna funcione como lo está haciendo ahora, lo que significa que ha seguido reconociendo las variantes que surgen”, explicó Añéz.
“El adyuvante es responsable de estas fuertes respuestas humorales que hemos observado hasta ahora frente a todas las variantes que hemos probado”.
Un miembro del liderazgo de la Sociedad de Enfermedades Infecciosas de América (IDSA) siente que se están logrando algunos avances en el Congreso para esta legislación de resistencia a los antimicrobianos.
Play Video
To the general public and those outside the Washington DC beltway, the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act seems like it is stalled and might not have a chance to get passed.
Initially introduced in Congress by US Senators Michael Bennet (D-Colo.) and Todd Young (R-Ind.) in September of 2020, Bennet and Young along with and Representatives Mike Doyle (D-Pa.) and Drew Ferguson (R-Ga.) reintroduced the bill in June 2021.
For the uninitiated, the Pasteur Act is a bipartisan, bicameral piece of legislation aimed to incentivize innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics, and ensure domestic availability when needed.
As the prospective legislation was drafted over two years ago, it seems as if the bill has languished in getting through Congress.
However, to Amanda Jezek, senior vice president of public policy and government relations at IDSA, she has a different perspective.
“We are fighting to make sure we have a much stronger antibiotic arsenal because we don’t want any single physician to tell their patient I’m sorry we are out of options,” Jezek said in an interview at ID Week.
She is optimistic that the legislation will be passed. She said there are 65 bipartisan cosponsors in Congress for the bill. As part of trying to emphasize the bill, members of the IDSA Board members who were in Washington this past week visited with Health and Human Services (HHS) Secretary Xavier Becerra as well as different members of Congress. When talking to staff of republican and democratic congressional members there is a bipartisan appeal to the Pasteur Act according to Jezek.
“Everywhere we go, people say, ‘yes we need action on AMR,’” Jezek stated. “We are excited to keep building the momentum and get this bill across the finish line and send it to the President’s desk.”
Jezek sat down to talk with Contagion who offered some insights into what IDSA is doing in terms of advocacy overall as well as with the Pasteur Act.
Jacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.
Play Video
Rodney Rohde, SV, SM, MB (ASCP), FACSc: Hello, and welcome to this Peer Exchange titled “Recent Approvals in Vaccination Against SARS-CoV-2 and the Omicron Subvariants”. My name is Dr Rodney E. Rohde. I’m a regents professor, a research dean, and the chair of the clinical laboratory science program at Texas State University in the College of Health Professions in San Marcos, Texas. It’s my honor to join you guys. Joining me are my colleagues, and I’ll let each of them introduce themselves.
Jacinda Abdul-Mutakabbir, PharmD: Hi, everyone. My name is Dr Jacinda Abdul-Mutakabbir, but I go by Dr JAM or JAM. I’m an assistant professor at Loma Linda University in Loma Linda, California.
Madeline King, PharmD, BCIDP: Hi, my name is Dr Madeline King. I’m an infectious disease clinical pharmacist, and I practice as an outpatient infectious disease pharmacist at Cooper University Hospital in Camden, New Jersey.
Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP: Hi, everyone. I’m Dr Wendy Wright, an adult and family nurse practitioner, and the owner of 2 nurse practitioner owned and operated primary care clinics in New Hampshire. It’s truly my pleasure to be with all of you.
Rodney Rohde, SV, SM, MB (ASCP), FACSc: It’s great to meet everyone and hear your backgrounds. Our discussion will be focused on providing an overview of some of the recently approved SARS-CoV-2 booster shots, highlighting some of the recommendations and how to discuss these vaccination options with patients. Welcome, everyone. Let’s get started.
In our first segment we’ll talk about a general overview around SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] and the variants involved in that outbreak and pandemic. Dr JAM, I’ll start with you. Would you like to discuss the difference between the original SARS-CoV-2 strain, which was discovered about 2½ years ago, and the subsequent subvariants that have been percolating through society since that time?
Jacinda Abdul-Mutakabbir, PharmD: Thank you for that question, Rodney. It’s one I get often. When we think about the differences between the original COVID-19 strain, or what we in the community call the OG strain, and then compare that with the subvariants that we see, it’s just a matter of genetic mutations that multiply and then cause these subvariants to be prevalent.
Then I come into this place of asking, how are these subvariants identified? How is it that we named them? And so on and so forth. This was a learning moment for me. We use the Phylogenetic Assignment of Named Global Outbreak Lineages, or the PANGOLIN nomenclature. That’s how we end up with B.1,B.5, and so on. Then the World Health Organization designates specific names to the variant. At this point, we’re 15 letters into the Greek alphabet at Omicron. They started with Alpha. Those are the differences we see in terms of our original COVID-19 strain and the subvariants that we’re seeing.
Rodney Rohde, SV, SM, MB (ASCP), FACSc: Thanks for that explanation. As a virologist, I’m often answering those questions as well. As many of you know, a lot of these viruses sometimes get named from their origin. We’ve tried to stop doing that so that we can quit placing a geographic location or some other nomenclature that might be looked upon as a stigma. That’s the reasoning behind some of that. Thank you, Dr JAM, for that information.
